Mutant HER2 needs mutant HER3 to be an effective oncogene.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34467245.
- Also identified by DOI 10.1016/j.xcrm.2021.100361 and PMC identifier 8385292.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hanker et al. reveal that co-occurring missense mutations in the human epidermal growth factor receptor 2 (HER2) and its catalytically inactive homolog HER3 synergize to promote oncogenic signaling by the HER2/HER3 complex.
Medical subject headings
- Erb-b2 Receptor Tyrosine Kinases
- Receptor, ErbB-3